News
AFMD
1.190
+0.85%
0.010
Affimed’s Potential in Cancer Treatment: Navigating Challenges with Strategic Partnerships
TipRanks · 2d ago
Affimed (AFMD) Gets a Buy from Truist Financial
TipRanks · 5d ago
Affimed price target lowered to $11 from $15 at Wells Fargo
TipRanks · 5d ago
Affimed price target lowered to $7 from $10 at H.C. Wainwright
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Ardent Health Partners, Inc. (ARDT)
TipRanks · 5d ago
Affimed stock plunges 23% on AFM24 study update
Seeking Alpha · 5d ago
Affimed’s Promising Clinical Update on NSCLC Treatment
TipRanks · 6d ago
Affimed’s AFM24/atezolizumab combination shows positive results in NSCLC trial
TipRanks · 6d ago
Affimed Reports Results for Cancer Therapy in NSCLC Patients
Benzinga · 6d ago
Weekly Report: what happened at AFMD last week (1209-1213)?
Weekly Report · 12/16 12:18
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)
TipRanks · 12/16 06:10
Affimed Price Target Cut to $15.00/Share From $20.00 by Wells Fargo
Dow Jones · 12/12 19:28
Affimed Is Maintained at Overweight by Wells Fargo
Dow Jones · 12/12 19:28
Wells Fargo Maintains Overweight on Affimed, Lowers Price Target to $15
Benzinga · 12/12 19:18
Affimed Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 12/10 12:35
HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target
Benzinga · 12/10 12:24
Promising Efficacy and Safety of Affimed’s Therapies Supports Buy Rating
TipRanks · 12/10 11:25
Affimed N.V. Reports Promising 40% Complete Remission Rate for AFM28 in Heavily Pretreated R/R AML Patients
Barchart · 12/09 22:42
Affimed reports ‘promising’ Phase 1 efficacy, safety data for AFM28
TipRanks · 12/09 18:35
Affimed Reports Phase 1 Efficacy And Safety Data For AFM28 In Relapsed/Refractory Acute Myeloid Leukemia; AFM28, A Bispecific, Tetravalent Innate Cell Engager Targeting CD123 And CD16A, Achieved A 40% Composite Complete Remission Rate At The Highest Dose Level In Heavily Pretreated R/R AML Patients
Benzinga · 12/09 18:31
More
Webull provides a variety of real-time AFMD stock news. You can receive the latest news about Affimed through multiple platforms. This information may help you make smarter investment decisions.
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.